Decreased CD38 expression triggered by IL-6 in MM cells is further associated with reduced sensitivity to anti-CD38 MoAb (i.e., daratumumab), providing a new molecular mechanism to support the immunosuppressive function of IL-6 in the BM microenvironment. The gene discussed is IL6; the disease is Miyoshi myopathy.